Phase 1 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able and willing to sign a written consent form agreeing to take part
• People who are 18 years of age or older at the time of signing the consent form
• People who have been diagnosed with an advanced solid tumour cancer (confirmed by laboratory testing of tissue or cells) that cannot be surgically removed and/or has spread to other parts of the body
• Male participants who agree to use contraception and not donate sperm or attempt to father a child during the trial
• Female participants who are not pregnant, not breastfeeding, and not considered to be of childbearing potential
• People whose cancer can be measured using standard imaging criteria (called RECIST 1.1), as assessed by the trial site
• People who are able to provide a tumour tissue sample
• People willing to have a fresh tumour biopsy taken at the start of the trial and during treatment, if a previously stored tissue sample is not available
• People with a general health and activity level rated as 0 or 1 on a standard scale used by oncology researchers (meaning fully active or able to carry out light activity) (confirm with trial site)
• People whose life expectancy is estimated to be at least 12 weeks, as judged by the treating doctor
• People whose liver, kidney, and other organ functions are within acceptable levels (confirm with trial site)

Who may not be able to join:

• Women of childbearing potential who have a positive pregnancy blood test within 72 hours before starting treatment
• People who have taken part in another clinical trial using an experimental treatment within the 4 weeks before starting this trial
• People who have received certain anti-cancer treatments — including non-antibody-based immunotherapy, retinoid therapy, or hormonal therapy — within 2 weeks before starting treatment
• People who have received an antibody-based anti-cancer therapy within 4 weeks before starting treatment
• People who have received targeted therapy or small molecule drugs within 2 weeks, or within 5 half-lives of the drug (whichever period is longer), before starting treatment
• People who received platinum-based chemotherapy and whose cancer continued to grow or spread within 4 weeks of starting that treatment
• People who have previously received a type of drug called an antibody-drug conjugate (ADC) that uses a specific component called MMAE
• People who have had radiotherapy to a small area within 2 weeks, or radiotherapy covering a large area of the body within 4 weeks, before starting the trial
• People who have received certain white blood cell-stimulating injections (G-CSF or GM-CSF) within 7 days before starting the trial
• People who have received a live or weakened-live vaccine within 30 days before the first dose
• People who have a condition affecting the immune system, or who are taking steroid medications at a dose higher than the equivalent of 10 mg of prednisone per day, or any other immune-suppressing medication within 7 days before the first dose
• People who have another cancer (separate from the one being studied) that is still active or has required treatment within the past 3 years
• People who have active cancer that has spread to the brain or the lining around the brain or spinal cord
• People who have a known severe allergic reaction (Grade 3 or higher) or known allergy to the trial drug LNCB74 or any of its ingredients
• People who have a history of, or currently have, a non-infectious lung condition called pneumonitis or interstitial lung disease that required steroid treatment
• People who have moderate or severe nerve damage affecting sensation or movement (Grade 2 or higher) (confirm with trial site)
• People who have active or ongoing eye or corneal conditions requiring treatment, or any significant corneal disease
• People who have an active infection that requires treatment with antibiotics or other systemic medications
• People who have had major surgery within 4 weeks before starting the trial drug
• People who still have significant side effects from previous cancer treatment or surgery (other than hair loss) that have not resolved or returned to a mild level
• People who have previously received an organ or tissue transplant from another person
• People who have uncontrolled or significant heart or blood vessel disease
• People who have serious or uncontrolled medical conditions
• People who are receiving nutrition entirely through an intravenous line (called total parenteral nutrition)
• People who have had a bowel obstruction within one month before the screening period
• People who have needed a procedure to drain significant fluid build-up in the abdomen within 2 weeks before screening
• People who have a known history of HIV infection with a serious related illness in the past year, or a current immune cell count below a certain level (confirm with trial site)
• People who have active Hepatitis B or active Hepatitis C infection
• People who have any other condition, treatment, or circumstance that could affect the trial results or prevent them from completing the full study
• People who have a known psychiatric condition or substance use disorder that would make it difficult to follow the requirements of the trial

Important: Always verify eligibility with the trial site directly before applying.